Linked Life Data

18329749

Source:http://linkedlifedata.com/resource/pubmed/id/18329749

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-3-27
pubmed:abstractText
Chronic hepatitis C (HCV) infection remains a major health problem worldwide. The current standard of care is a combination of pegylated interferon-alpha and ribavirin. Considering the length of antiviral therapy, as well as its side effects and costs, accurate prediction of treatment response prior to initiation of treatment is critical. In addition to viral, demographic and environmental factors, host genetic diversity is believed to contribute to the spectrum of clinical outcomes of chronic HCV. The development of high-throughput technologies provides opportunities to define patterns of gene expression that are associated with certain disease outcomes and/or response to therapy. This article reviews genomics-based predictors of pre-treatment response to antiviral therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0168-8278
pubmed:author
pubmed:issnType
Print
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
708-13
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients.
pubmed:affiliation
Multiorgan Transplant Program, University Health Network, University of Toronto, Toronto General Hospital, 585 University Avenue, Toronto, Ontario, Canada.
pubmed:publicationType
Journal Article